Market closedNon-fractional
Mersana Therapeutics/MRSN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Mersana Therapeutics
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
Ticker
MRSN
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Cambridge, United States
Employees
123
Website
www.mersana.com
MRSN Metrics
BasicAdvanced
$242M
Market cap
-
P/E ratio
-$1.13
EPS
1.49
Beta
-
Dividend rate
Price and volume
Market cap
$242M
Beta
1.49
Financial strength
Current ratio
3.512
Quick ratio
3.429
Long term debt to equity
89.191
Total debt to equity
120.475
Interest coverage (TTM)
-26.43%
Management effectiveness
Return on assets (TTM)
-33.91%
Return on equity (TTM)
-292.19%
Valuation
Price to revenue (TTM)
6.183
Price to book
8.68
Price to tangible book (TTM)
8.68
Price to free cash flow (TTM)
-1.361
Growth
Revenue change (TTM)
18.40%
Earnings per share change (TTM)
-46.66%
3-year revenue growth (CAGR)
258.96%
3-year earnings per share growth (CAGR)
-10.66%
What the Analysts think about MRSN
Analyst Ratings
Majority rating from 9 analysts.
MRSN Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$9.2M
-14.02%
Net income
-$19M
-1.03%
Profit margin
-209.78%
15.11%
MRSN Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.47
-$0.35
-$0.16
-$0.16
-
Expected
-$0.44
-$0.36
-$0.16
-$0.18
-$0.17
Surprise
6.47%
-3.29%
-2.64%
-11.60%
-
MRSN News
AllArticlesVideos
Mersana Therapeutics to Present at Upcoming Investor Conferences
GlobeNewsWire·2 months ago
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·3 months ago
Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Mersana Therapeutics stock?
Mersana Therapeutics (MRSN) has a market cap of $242M as of July 27, 2024.
What is the P/E ratio for Mersana Therapeutics stock?
The price to earnings (P/E) ratio for Mersana Therapeutics (MRSN) stock is 0 as of July 27, 2024.
Does Mersana Therapeutics stock pay dividends?
No, Mersana Therapeutics (MRSN) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Mersana Therapeutics dividend payment date?
Mersana Therapeutics (MRSN) stock does not pay dividends to its shareholders.
What is the beta indicator for Mersana Therapeutics?
Mersana Therapeutics (MRSN) has a beta rating of 1.49. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Mersana Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.